229 related articles for article (PubMed ID: 26881560)
1. Complete response of a recurrent-metastatic liposarcoma with dedifferentiated histological features following the administration of trabectedin and review of literature.
Kus T; Aktas G; Kalender ME; Tutar E; Ulker E; Camci C
J Cancer Res Ther; 2015; 11(4):974-6. PubMed ID: 26881560
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin--a targeted chemotherapy?
von Mehren M
Lancet Oncol; 2007 Jul; 8(7):565-7. PubMed ID: 17613417
[No Abstract] [Full Text] [Related]
4. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
5. Prolonged disease stability with trabectedin in two monorenal patients with retroperitoneal sarcoma.
Bruder F; Massa D; Barca M; Contu V; Airoldi M; Crova A
Tumori; 2014; 100(3):e63-6. PubMed ID: 25076252
[TBL] [Abstract][Full Text] [Related]
6. [A Case of Giant Retroperitoneal Liposarcoma Resected after Trabectedin Chemotherapy].
Ishiguro T; Muta Y; Ito T; Chika N; Hatano S; Amano K; Muramatsu S; Suzuki O; Toyomasu Y; Fukuchi M; Kumagai Y; Ishibashi K; Mochiki E; Ishida H
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2132-2134. PubMed ID: 30692308
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of trabectedin for the treatment of liposarcoma.
Zijoo R; von Mehren M
Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.
Gronchi A; Bui BN; Bonvalot S; Pilotti S; Ferrari S; Hohenberger P; Hohl RJ; Demetri GD; Le Cesne A; Lardelli P; Pérez I; Nieto A; Tercero JC; Alfaro V; Tamborini E; Blay JY
Ann Oncol; 2012 Mar; 23(3):771-776. PubMed ID: 21642514
[TBL] [Abstract][Full Text] [Related]
9. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
Uboldi S; Calura E; Beltrame L; Fuso Nerini I; Marchini S; Cavalieri D; Erba E; Chiorino G; Ostano P; D'Angelo D; D'Incalci M; Romualdi C
PLoS One; 2012; 7(4):e35423. PubMed ID: 22523595
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.
Saponara M; Stacchiotti S; Gronchi A
Expert Rev Anticancer Ther; 2016 May; 16(5):473-84. PubMed ID: 27043847
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
D'Incalci M; Badri N; Galmarini CM; Allavena P
Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
[TBL] [Abstract][Full Text] [Related]
12. The intriguing patterns of tumor response to trabectedin.
Sanfilippo R; Casali PG
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
[TBL] [Abstract][Full Text] [Related]
13. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
Frapolli R; Tamborini E; Virdis E; Bello E; Tarantino E; Marchini S; Grosso F; Sanfilippo R; Gronchi A; Tercero JC; Peloso G; Casali P; Pilotti S; D'Incalci M
Clin Cancer Res; 2010 Oct; 16(20):4958-67. PubMed ID: 20732964
[TBL] [Abstract][Full Text] [Related]
14. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
[TBL] [Abstract][Full Text] [Related]
15. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.
Blay JY; Casali P; Nieto A; Tanović A; Le Cesne A
Future Oncol; 2014 Jan; 10(1):59-68. PubMed ID: 23987833
[TBL] [Abstract][Full Text] [Related]
17. Recurrent liposarcomas of the abdomen and retroperitoneum: three case reports.
Fotiadis C; Zografos GN; Karatzas G; Papachristodoulou A; Sechas MN
Anticancer Res; 2000; 20(1B):579-83. PubMed ID: 10769729
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
Assi T; Kattan J; El Rassy E; Honore C; Dumont S; Mir O; Le Cesne A
Cancer Treat Rev; 2019 Jan; 72():37-44. PubMed ID: 30468937
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
Martinez-Cruzado L; Tornin J; Rodriguez A; Santos L; Allonca E; Fernandez-Garcia MT; Astudillo A; Garcia-Pedrero JM; Rodriguez R
Neoplasia; 2017 Jun; 19(6):460-470. PubMed ID: 28494349
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease.
Thariat J; Etienne-Grimaldi MC; Launay-Vacher V; Soto-Matos A; Fernandez-Teruel C; Ghafari T; Marcy PY; Milano G; Renée N; Gastaud L; Thyss A
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1363-7. PubMed ID: 21850465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]